HIGHLIGHTS
- who: Daniel Su00e1nchez-Tejerina et al. from the Neuromuscular and Rare Diseases EU have published the research: New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies, in the Journal: (JOURNAL) of 31/08/2022
- what: In this review, the aims were to analyze the recent literature and evidence on these innovative therapies and to briefly discuss the impact of therapy on clinical outcomes, acute exacerbations, adverse events, tolerability, and quality of life. One of the most dangerous complications expected with complement inhibitor therapies is infection with encapsulated bacteria, mainly Neisseria meningitides, although all patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.